LILRB2

LILRB2

LILRB2 Informations sur la molécule

Molecule Name
Leukocyte immunoglobulin-like receptor subfamily B member 2
Alias de la molécule
LILRB2,ILT4,LIR2,MIR10,CD85d
Drug Development Progress
Nombre de médicaments cliniques11
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
Leukocyte immunoglobulin-like receptor 2,CD85 antigen-like family member D,Immunoglobulin-like transcript 4,ILT-4,Monocyte/macrophage immunoglobulin-like receptor 10,MIR-10,CD_antigen: CD85d,LILRB2,Leukocyte Immunoglobulin Like Receptor B2,Leucocyte Ig-Like Receptor B2,MIR10,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 2,Ig-Like Transcript 4,Myeloid Inhibitory Receptor 10,CD85d Antigen,ILT4,LIR2,CD85d,LIR-2,LIRB2
Contexte de la molécule
Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB2 Liste de produits

Species
  • Human(4)
  • Cynomolgus(2)
Tag
  • His Tag(2)
  • His Tag & Avi Tag(2)
  • Fc Tag(1)
  • Fc Tag & Avi Tag(1)
Host
  • HEK293(6)
Conjugate
  • Biotin-labeled(3)
  • Unconjugated(3)
Grade
  • RUO(6)
Low Endotoxin
  • Yes(1)
  • No(5)
MoleculeCat. No.Product NameEspèceHostStructurePurityActivitySize&PriceAdd to Cart
LILRB2
HOTAvitag
LI2-H82E7
Biotinylated Human LILRB2 / CD85d / ILT4 Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$380.00

25ug
LILRB2
Human LILRB2 / CD85d / ILT4 Protein, His Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$310.00

100ug
LILRB2
HOTAvitag
LI2-H82F5
Biotinylated Human LILRB2 / CD85d / ILT4 Protein, Fc,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$380.00

25ug
LILRB2
Human LILRB2 / CD85d / ILT4 Protein, Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$310.00

100ug
LILRB2
Cynomolgus LILRB2 / CD85d / ILT4 Protein, His Tag
Cynomolgus
HEK293
SDS-PAGE

$270.00

100ug
LILRB2
Avitag
LI2-C82E3
Biotinylated Cynomolgus LILRB2 / CD85d / ILT4 Protein, His,Avitag™
Cynomolgus
HEK293
SDS-PAGE

$360.00

25ug
You Have Viewed 1-6 Of 6 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Plateforme de commerce de projets d'anticorps

Nom du projetPhase du projetType de moléculeSource de moléculeDomain thérapeutiqueIndication
LILRB2 mAb - 01PCCMonoclonalHumanized MouseSolid TumorSolid tumor
Nom du projet
LILRB2 mAb - 01
Phase du projet
PCC
Type de molécule
Monoclonal
Source de molécule
Humanized Mouse
Domain thérapeutique
Solid Tumor
Indication
Solid tumor
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
PolzastobartJTX-8064Phase 2 ClinicalJounce Therapeutics Inc
Neoplasms
Details
IO-108IO-108Phase 2 ClinicalYiming Biomedical Technology (Hangzhou) Co Ltd
Liver Neoplasms; Solid tumours
Details
MK-4830MK-4830Phase 2 ClinicalAgenus Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Solid tumours
Details
SPX-303SPX-303Phase 2 ClinicalSparX Biopharmaceutical Corp
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
OR-502OR502; OR-502Phase 2 ClinicalOncoResponse Inc
Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Skin Melanoma; Solid tumours
Details
NGM-707NGM-707Phase 2 ClinicalMerck & Co, NGM Biopharmaceuticals Inc
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Glioblastoma; Melanoma; Mesothelioma; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms
Details
AK-150 (Akeso)AK150; AK-150Phase 1 Clinical
Solid tumours
Details
CHS-1000CHS-1000Phase 1 ClinicalCoherus Biosciences Inc
Solid tumours
Details
BMS-986406BMS-986406; ONO-7226Phase 1 ClinicalBristol-Myers Squibb Company
Neoplasms
Details
CDX-585CDX-585; BSI-585Phase 1 ClinicalBiosion Inc, Celldex Therapeutics
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms
Details
ES-009ES-009Phase 1 ClinicalElpiscience (Shanghai) Biopharma Ltd
Neoplasms; Solid tumours
Details
Customer Reviews